Lithium Americas (NYSE:LAC) Stock

Lithium Americas

Lithium Americas is a pure-play lithium producer. The firm owns 62% of one resource, Thacker Pass, which is located in northwest Nevada, with automaker General Motors owning the remaining 38%. Thacker Pass is under construction and expected to begin production in 2028. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.

Lithium Americas Corp

LAKE AREA CORN PROC UTS D by Lake Area Corn Processors LLC

LAPCO HOLDINGS LTD by LAPCO HOLDINGS LTD.

LAKE AREA CORN PROC UTS B by Lake Area Corn Processors LLC

Lachlan Star Ltd

Lacroix Group

News

LTRX

Lantronix Reaches Cooperation Agreement With Chain Of Lakes Investment Group, Appoints Jim Auker To Board

HC Wainwright &amp; Co. analyst Andrew Fein assumes Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) with a Buy rating and announces Price Target of $23.

Price Target

Initiation

Analyst Ratings

CADL

HC Wainwright & Co. Assumes Candel Therapeutics at Buy, Announces Price Target of $23

<ul>
<li>Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxylanthanum Carbonate (OLC).</li>
<li>No other concerns stated, including pre-clinical, clinical, or safety data.</li>
<li>The Company identified a second manufacturing vendor that has already produced OLC drug product, which could also be used to support the resolution of the Clinical Manufacturing and Controls (CMC) issues identified in the CRL.</li>
<li>The Company plans to immediately request a Type A meeting with the FDA to align on next steps.</li>
<li>Unicycive currently has an unaudited cash balance of approximately $20.7 million, with cash runway currently expected into the second half of 2026</li>
</ul>

Biotech

Health Care

General

UNCY

The FDA Issues Complete Response Letter For Unicycive Therapeutics' New Drug Application For Oxylanthanum Carbonate To Treat Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis

Walker & Dunlop Secures $170M To Refinance Post District, A Class A, Mixed-Use Complex Containing 580 Residential Units In Downtown Salt Lake City, Utah

COIN

WBUY

Webuy Global Partners With Coinbase Commerce To Launch Stablecoin Payment Option For Global Travel And E-Commerce Offerings

NLSP

NLS Pharma Completes Second And Final $1M Closing Of $3M Equity Financing Of Preferred Shares And Warrants From March 2025

President Donald Trump escalated his war of words with Federal Reserve Chair Jerome Powell on Sunday, accusing him of keeping interest rates &#8220;artificially high&#8221; and insisting the benchmark should drop to "1% or 2%&#8221;, half of what it is now.
What Happened: Appearing on Fox News' "Sunday Morning Futures," Trump <a href="https://www.foxbusiness.com/politics/trump-blasts-powell-says-any-replacement-would-better-refinancing-9t-debt">called</a> Powell a "stupid person" and &#8220;a bad person,&#8221; claiming the Fed chief's policies force the government to refinance roughly $9 trillion in debt at punitive costs.
&#8220;We have a bad Fed chairman," he said. "But&#8230; the numbers are so good it doesn't even matter that he keeps the rates artificially high.&#8221;
The President's broadside followed months of threats to fire Powell, warnings that rattled bond markets earlier this year. After legal advisers cautioned that dismissing the chair could <a href="https://www.benzinga.com/25/05/45579414/supreme-court-says-trump-cant-fire-jerome-powellthe-fed-a-uniquely-structured-quasi-private-entity">violate the Fed's independence</a>, Trump shifted to pledging a successor who will slash borrowing costs. "I know within <a href="https://www.benzinga.com/news/25/06/46115346/trump-powell-fed-chairman-odds-dollar">three or four people</a> who I'm going to pick," he told reporters last week at a NATO summit, labeling Powell "terrible," according to Reuters.
See also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46163659/senate-republicans-propose-313-billion-cut-in-medicaid-spending-in-trumps-big-beautiful-bill">Senate Republicans Propose $313 Billion Cut In Medicaid Spending In Trump&#8217;s &#8216;Big, Beautiful Bill&#8217;</a>
Why It Matters: Treasury Secretary Scott Bessent <a href="https://www.cnbc.com/2025/06/27/cnbc-transcript-us-treasury-secretary-scott-bessent-speaks-with-cnbcs-morgan-brennan-on-closing-bell-overtime-today.html">said</a> on CNBC that the administration could nominate a replacement as soon as October, raising the prospect of a &#8220;shadow Fed&#8221; months before Powell's term ends in May 2026. Trump confirmed he would not appoint anyone "who doesn't want to cut rates," and singled out former Fed governor Kevin Warsh as "very talented," though he stopped short of endorsing him, states Reuters.
The Fed's target range stands at <a href="https://www.benzinga.com/markets/economic-data/25/06/46087650/feds-schmid-says-wait-and-see-approach-right-for-rate-policy-as-tariff-fallout-still-unclear">4.25%–4.5%</a> after aggressive 2024 hikes. Policymakers signaled modest easing later this year but argue larger cuts risk reigniting tariff-driven inflation.
Critics warn that overt <a href="https://www.benzinga.com/news/25/04/45027556/after-powell-trumps-fed-nominee-will-be-a-loyal-soldier-says-peter-schiff-willing-to-sacrifice-the-dollar-create-inflation-as-needed">political pressure</a> could erode the central bank's credibility and unsettle global markets. A report from the Peterson Institute suggests that undermining the Fed&#8217;s independence could lead to a&nbsp;<a href="https://apnews.com/article/trump-inflation-tariffs-taxes-immigration-federal-reserve-a18de763fcc01557258c7f33cab375ed" target="_blank" rel="noopener">persistent</a>&nbsp;2 percentage point annual increase in inflation, <a href="https://apnews.com/article/trump-inflation-tariffs-taxes-immigration-federal-reserve-a18de763fcc01557258c7f33cab375ed">according</a> to an AP report.
Read next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46163670/trumps-bills-over-bonds-strategy-can-spell-doom-for-the-dollar-warns-craig-shapiro-got-gold-bitcoin">Trump&#8217;s &#8216;Bills Over Bonds&#8217; Strategy Can Spell Doom For The Dollar, Warns Craig Shapiro: &#8216;Got Gold, Bitcoin?&#8217;</a></li>
</ul>
Image via Shutterstock

Politics

Economics

Federal Reserve

Markets

Donald Trump Calls Fed Chair Jerome Powell A 'Bad Person' Who Keeps Rates 'Artificially High,' Says Benchmark Should Drop By Half

HC Wainwright &amp; Co. analyst Joseph Pantginis initiates coverage on Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) with a Buy rating and announces Price Target of $42.

EWTX

HC Wainwright & Co. Initiates Coverage On Edgewise Therapeutics with Buy Rating, Announces Price Target of $42

<ul>
<li>In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plus darolutamide in men with metastatic castration resistant prostate cancer ("mCRPC"). the six-month radiographic progression free survival ("rPFS") rate was 66%.</li>
<li>In a Phase 2 clinical trial of gedatolisib plus trastuzumab-pkrb as 3L+ therapy in patients with HER2+ metastatic breast cancer ("mBC"), the objective response rate ("ORR") was 43%.</li>
<li>No patients discontinued gedatolisib due to a treatment-related adverse event ("AE") in either clinical trial</li>
</ul>

CELC

Celcuity Announced Preliminary Clinical Data For Gedatolisib In Two Early-phase Clinical Trials

HCAI

Huachen AI Parking Enters Into Non-Binding Cooperative Agreement With Hangzhou Qianhui To Enhance Two-Wheeled E-Charging Infrastructure

HC Wainwright &amp; Co. analyst Robert Burns maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $47 to $53.

EXEL

HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $53

JinkoSolar Holding Delivers Of Tiger Neo Modules To Support Construction Of Spain's Segovia Solar Cluster

HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiates coverage on Aardvark Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) with a Buy rating and announces Price Target of $40.

AARD

HC Wainwright & Co. Initiates Coverage On Aardvark Therapeutics with Buy Rating, Announces Price Target of $40

TNXP

Tonix Pharma Added To Russell 3000 Index, With Automatic Inclusion In Russell 2000 Index, Effective June 30, 2025, As Part Of 2025 Russell Indexes Reconstitution

LASE

Laser Photonics' Beamer Laser Marking Systems Subsidiary Bags New Orders For T-Series And B-Series Laser Marking Machines

The poster detailed two important observations that support Cassava's plan to initiate human clinical studies in H1 2026 to evaluate simufilam as a treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy:
<ul>
<li>Preclinical proof-of-concept: Treatment with simufilam alleviated neuronal abnormalities and reduced seizure frequency by 60% compared to vehicle in a mouse model of focal onset seizures.</li>
<li>Clinical safety: Data from two human Phase 3 studies in Alzheimer's disease demonstrated a favorable safety profile</li>
</ul>

SAVA

Cassava Sciences Presented A Poster At The TSC International Research Conference

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older
CAMBRIDGE, MA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 30, 2025 / Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) today announced positive results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% (95% CI; 16.7%, 35.4%) in the overall study population. Additionally, strong rVE was observed for each influenza strain contained in the vaccine, including A/H1N1 (rVE=29.6%), A/H3N2 (rVE=22.2%), and the B/Victoria lineages (rVE=29.1%). Subgroup analyses confirmed a consistently strong rVE point estimate across age groups, risk factors and previous influenza vaccination status. In participants aged 65 years and older, mRNA-1010 demonstrated an rVE of 27.4%.
In a previous Phase 3 study, mRNA-1010 had already demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal influenza vaccine. [1]
According to the CDC, seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-2025 season. [2] More than 600,000 Americans were hospitalized due to flu-related illness last year, leading to substantial direct and indirect costs, as well as widespread disruption to daily life and work. [3]
P304 (<a href="https://pr.report/bx98"> NCT06602024</a> ) is a Phase 3, randomized, observer-blind, active-controlled, case-driven, pivotal efficacy, immunogenicity and safety study. The trial enrolled 40,805 adults aged 50 years and older across 11 countries. Participants were randomly assigned to receive either a single dose of mRNA-1010 or a standard-dose licensed comparator, with a median follow-up of six months.
Safety and tolerability of mRNA-1010 were consistent with reported results from a previous Phase 3 study. [4] The majority of solicited adverse reactions (SARs) were mild. Injection site pain was the most common local SAR, and fatigue, headache and myalgia were the most common systemic SARs reported. There were no significant differences between the groups in the rates of unsolicited adverse events, serious adverse events, or adverse events of special interest.
Moderna plans to present these data at an upcoming medical conference and submit for peer-reviewed publication. The Company will engage with regulators on filing submissions for mRNA-1010.

MRNA

Moderna Reports Results From Phase 3 Efficacy Study Evaluating rVE Against Influenza Illness Of mRNA-1010 Versus Licensed Standard-Dose Seasonal Influenza Vaccine In Adults

HC Wainwright &amp; Co. analyst Brandon Folkes initiates coverage on Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy rating and announces Price Target of $20.

CRMD

HC Wainwright & Co. Initiates Coverage On Cormedix with Buy Rating, Announces Price Target of $20

PLTR

Palantir And Accenture Federal Launch Landmark Collaboration To Empower Government Agencies With AI-Enabled Decision-Making And Operational Resilience

Trading Halt: Halted at 7:00:00 a.m. ET - Trading Halt: Halt News Pending

Press Releases

Lithium Americas Announces $250 Million Strategic Investment from Orion Resource Partners for Thacker Pass

Gabelli Funds to Host 16th Annual Specialty Chemicals Symposium Thursday, March 20, 2025

Lithium Americas Reports 2024 Full Year Results

Lithium Americas Announce FID for Thacker Pass Phase 1 and Closes Strategic Investment from Orion Resource Partners

Comments

Lithium Americas

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL